Factors Associated With Outcomes After a Second CD19-Targeted CAR T-Cell Infusion for Refractory B-Cell Malignancies
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Factors Associated With Outcomes After a Second CD19-Targeted CAR T-Cell Infusion for Refractory B Cell Malignancies
Blood 2020 Sep 23;[EPub Ahead of Print], J Gauthier, ED Bezerra, AV Hirayama, S Fiorenza, A Sheih, CK Chou, EL Kimble, BS Pender, RM Hawkins, A Vakil, TD Phi, RN Steinmetz, AW Jamieson, M Bar, R Cassaday, A Chapuis, AJ Cowan, DJ Green, HP Kiem, F Milano, M Shadman, B Till, SR Riddell, DG Maloney, CJ TurtleFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.